Millennium Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Millennium Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,400	Closed	-$3.61M	–	6763
2023 Q2	$3.61M	Buy	35,400 +8,900	+34%	+$842K	﹤0.01%	2958
2023 Q1	$2.41M	Buy	+26,500	New	+$1.56M	﹤0.01%	3257
2022 Q2	–	Sell	-148,300	Closed	-$4.86M	–	7726
2022 Q1	$4.86M	Buy	+148,300	New	+$4.4M	﹤0.01%	2970
2021 Q4	–	Sell	-20,000	Closed	-$2.01M	–	7579
2021 Q3	$2.01M	Buy	+20,000	New	+$2.34M	﹤0.01%	3914
2021 Q2	–	Sell	-20,000	Closed	-$1.99M	–	7308
2021 Q1	$1.99M	Buy	20,000 +5,000	+33%	+$583K	﹤0.01%	3536
2020 Q4	$1.85M	Sell	15,000 -20,000	-57%	-$2.63M	﹤0.01%	3297
2020 Q3	$3.41K	Sell	35,000 -15,000	-30%	-$1.87M	﹤0.01%	2173
2020 Q2	$7.8M	Buy	+50,000	New	+$7.6M	0.01%	1389
2020 Q1	–	Sell	-42,500	Closed	-$8.69M	–	4689
2019 Q4	$8.69M	Sell	42,500 -92,500	-69%	-$16.9M	0.01%	1494
2019 Q3	$10.8M	Buy	135,000 +39,800	+42%	+$3.38M	0.02%	1227
2019 Q2	$8.98M	Buy	+95,200	New	+$8.22M	0.01%	1337

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Millennium Management's RETA Position: Q3 2023 in Review

Millennium Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 556,264 shares — an estimated $56.7M sold.

Millennium Management first reported a position in RETA in Q4 2016 and held it in 23 quarters. The position peaked at $56.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Millennium Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Millennium Management sold 556,264 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $56.7M.
Millennium Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 23 quarters.
Millennium Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $56.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.